Telix Pharmaceuticals Limited (ASX: TLX) - Share Price

Current share price for TLX : $14.210 0.14 (1%)⁺

Telix Pharmaceuticals Limited (TLX), an ASX-listed company, is a global biopharmaceutical company engaged in the development and commercialization of targeted therapeutic and diagnostic radiopharmaceuticals, along with supporting medical technologies. Headquartered in Melbourne, Australia, Telix maintains strategic international operations across the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan.

TLX General Information ⁺

ASX Code	TLX
Website	N/A
Industry/Sector	Biotechnology
Market Cap ($M)	4,828
TLX Share Price	$14.210
Day High	$14.420
Day Low	$14.090
Last Close	$14.070
TLX Share Price Movement	$0.14 ( 1% )

Prices as at 16:35, 31 Jul 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

How TLX Plays a Part in Australian ETF Strategies

As a significant Australian company by market capitalisation, TLX is held across 37 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when TLX moves, funds like IMPQ, M1DS, MVE, VSO and FAIR that hold it can move with it.

For more concentrated exposure, ETFs such as IMPQ (eInvest Better Future (Managed Fund)) allocate about 4% to TLX , while the average exposure across all 37 ETFs that hold it is around 0.4% .

Top ETF holdings

eInvest Better Future (Managed Fund) (IMPQ) ~ 4%
Paradice Australian Mid Cap Fund Active ETF (M1DS) ~ 1.6%
VanEck S&P/ASX MidCap ETF (MVE) ~ 1.3%
Vanguard MSCI Australian Small Companies Index ETF (VSO) ~ 0.9%
BetaShares Australian Sustainability Leaders ETF (FAIR) ~ 0.7%

TLX Direct vs. ETF Alternatives

How does holding Telix Pharmaceuticals Limited (TLX) shares directly compare to ETFs that include it?

	TLX Direct	IMPQ ASX	M1DS CBOE	MVE ASX	VSO ASX	FAIR ASX
Holdings	1 company	41 holdings	44 holdings	50 holdings	193 holdings	77 holdings
Risk Profile	High	Medium	Medium	High	Medium	Medium
Asset Class	Share	Equities	Equities	Equities	Equities	Equities
Annual Cost	Brokerage only	0.89% p.a.	-	0.45% p.a.	0.3% p.a.	0.49% p.a.
Approx. Yield	-	2.13%	-	2.69%	4.91%	3.07%
Latest Franking	-	0%	-	48%	22.17%	49.31%

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not TLX's direct yield.

Telix Pharmaceuticals Limited (TLX) ETFs

37 ETFs hold Telix Pharmaceuticals Limited (TLX).

ETF	TLX Weight	MER	Yield
eInvest Better Future (Managed Fund) (IMPQ)	4%	0.89%	2.13%
Paradice Australian Mid Cap Fund Active ETF (M1DS)	1.6%	-	-
VanEck S&P/ASX MidCap ETF (MVE)	1.3%	0.45%	2.69%
Vanguard MSCI Australian Small Companies Index ETF (VSO)	0.9%	0.3%	4.91%
BetaShares Australian Sustainability Leaders ETF (FAIR)	0.7%	0.49%	3.07%
VanEck MSCI Australian Sustainable Equity ETF (GRNV)	0.6%	0.35%	3.68%
Global X Australia ex Financials & Resources ETF (OZXX)	0.5%	0.25%	5.21%
Betashares Australian Ex-20 Portfolio Diversifier ETF (EX20)	0.4%	0.25%	2.86%
Betashares Geared Australian Equity Fund (GEAR)	0.3%	2.11%	1.77%
Plato Global Alpha Fund Complex ETF (PGA1)	0.3%	0.85%	-

Telix Pharmaceuticals Limited (TLX) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Telix Pharmaceuticals Limited (TLX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Telix Pharmaceuticals Limited (TLX) price-sensitive announcements

TLX - Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress

Telix Pharmaceuticals Limited announced strong financial results for Q2 2026, reporting a

Telix Pharmaceuticals Limited (TLX)
21 Jul 2026 | 8:26 AM

TLX - FDA Alignment to Advance ProstACT Global Phase 3 Trial

Telix Pharmaceuticals Limited has announced its successful alignment with the U.S. Food an

Telix Pharmaceuticals Limited (TLX)
2 Jul 2026 | 10:07 AM

TLX - Convertible Bond Cleansing Notice

Telix Pharmaceuticals Limited has successfully priced an upsized US$600 million convertibl

Telix Pharmaceuticals Limited (TLX)
20 Apr 2026 | 4:47 PM

TLX - Telix Successfully Prices Upsized US$600M Convertible Bonds

Telix Pharmaceuticals Limited announced the successful pricing and upsizing of its US$600

Telix Pharmaceuticals Limited (TLX)
15 Apr 2026 | 8:14 AM

Telix Pharmaceuticals Limited (TLX) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID	Health Care	$4,828	Telix H1 2026 Results - Investor Webcast Notification	31 Jul 2026 8:30AM	$14.070	$14.210	risen by 1%
Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID	Health Care	$4,828	Change in substantial holding	24 Jul 2026 8:21AM	$15.170	$14.210	fallen by 6.33%
Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID	Health Care	$4,828	Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress	21 Jul 2026 8:26AM	$15.100	$14.210	fallen by 5.89%
Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID	Health Care	$4,828	Notification of cessation of securities - TLX	10 Jul 2026 8:24AM	$16.940	$14.210	fallen by 16.12%
Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID	Health Care	$4,828	Notification regarding unquoted securities - TLX	10 Jul 2026 8:24AM	$16.940	$14.210	fallen by 16.12%
Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID	Health Care	$4,828	Application for quotation of securities - TLX	10 Jul 2026 8:24AM	$16.940	$14.210	fallen by 16.12%

TLX Financial Summary

Year to Dec	NPAT	EPS	EPS chg (%)	PER	Yield (%)	Franking (%)
2025F	$122.66	$34.57	61.00%	82.53	0.00%	0.0%
2024F	$76.18	$21.47	5.70%	132.88	0.00%	0.0%
2023A	$65.73	$20.31	-174.80%	46.74	0.00%	0.0%

TLX Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 F	2025 F	2023 A	2024 F	2025 F	2023 A	2024 F	2025 F
CSL Limited (CSL)	$61,334M	0.1108	-0.1195	0.0168	13.7330	15.5966	15.3396	3.48%	2.85%	2.96%
Clinuvel Pharmaceuticals Limited (CUV)	$484M	0.0287	0.0000	0.0000	13.3565	0.0000	0.0000	0.52%	0.00%	0.00%
Immutep Limited (IMM)	$69M	0.1854	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Mesoblast Limited (MSB)	$2,649M	0.0301	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$4,927M	-1.3893	0.0000	-0.1426	0.0000	237.7049	277.2467	0.00%	0.00%	0.00%

TLX Directors

Name	Position	Start Date
Dr Christian Peter Behrenbruch	Chief Executive Officer, Managing Director	3 Jan 2017
Ms Jann E Skinner	Non-Executive Director	19 Jun 2018
Ms Marie Elizabeth McDonald	Non-Executive Director	3 Mar 2025
Mr David Gill	Non-Executive Director	11 May 2026
Dr Maria Rivas	Non-Executive Director	11 May 2026
Mr William (Bill) Jellison	Non-Executive Director	11 May 2026
Dr Mark Alexander Nelson	Non-Executive Director, Interim Chairman	17 Sep 2017

Telix Pharmaceuticals Limited (TLX) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
11 Jun 2026	GILL, David	Buy	Direct Shares	10,200	$9.434	$96,221.700
29 Apr 2026	BEHRENBRUCH, Christian	Buy	Indirect Shares	67,935	$14.671	$996,699.480
5 Nov 2025	BEHRENBRUCH, Christian	Exercise	Options	100,708	$4.380	$441,101.000

See all changes in directors' interest & trades for Telix Pharmaceuticals Limited (TLX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

TLX Management

Name	Position
Raphael Ortiz	Chief Executive Officer, Telix International
Kevin Richardson	Chief Executive Officer, Telix Precision Medicine
Richard Valeix	Chief Executive Officer, Telix Therapeutics
Darren Smith	Group Chief Financial Officer
David Cade	Group Chief Medical Officer
Mary Jessel	Group Chief of Clinical Affairs
Darren Patti	Group Chief Operating Officer
Lena Moran-Adams	Group General Counsel
Shomalin Naidoo	Interim Company Secretary
Meredith Crowe	Senior Vice President, People & Culture

TLX Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Telix Pharmaceuticals Limited (TLX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
28,187,775 (8.30%)	State Street Corporation and subsidiaries
22,419,015 (6.60%)	JPmorgan Chase & Co. and its affiliates
20,675,000 (6.10%)	Elk River Holdings Pty Ltd
20,675,000 (6.10%)	Gnosis Verwaltungsgesellschaft

TLX Calendar of Events

Date	Event
19 February 2027	Report (Annual)
19 February 2027	Report (Prelim)
20 August 2026	Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us